StreetInsider.com News Articles

Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges

Wed, 26 Aug 2026 08:35:00 -0400

The report reflects the current state of rural cardiovascular care in America and offers an exclusive roadmap for rural health organizations navigating ongoing workforce shortages and access challenges.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the release of a new edition of the company’s rural health report, “The State of Rural Hospitals and Cardiovascular Care,” aimed at helping rural healthcare leaders, policymakers, and community-based organizations improve cardiovascular care quality and outcomes in rural areas.

Ongoing Workforce Shortages and Access Challenges

The

Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges

Wed, 26 Aug 2026 08:35:00 -0400

Ongoing Workforce Shortages and Access Challenges

The

Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges

Wed, 26 Aug 2026 08:35:00 -0400

Ongoing Workforce Shortages and Access Challenges

The

Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges

Wed, 26 Aug 2026 08:35:00 -0400

Ongoing Workforce Shortages and Access Challenges

The

Form 8-K Cardio Diagnostics Holdi For: Aug 20

Thu, 20 Aug 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260820/26953265.html

Form 8-K Cardio Diagnostics Holdi For: Aug 20

Thu, 20 Aug 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260820/26953265.html

Cardio Diagnostics opens CLIA-certified lab in Iowa City

Tue, 18 Aug 2026 08:35:27 -0400

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has launched an in-house, high complexity CLIA-certified laboratory in Iowa City, Iowa, replacing the third-party arrangement the company previously used to process clinical samples.

The facility, which received its federal Clinical Laboratory Improvement Amendments license following an inspection that found no deficiencies, will handle end-to-end processing of the company's multi-omics clinical tests, Epi+Gen CHD™ and PrecisionCHD™, from sample receipt to result delivery. The company has also secured out-of-state licenses from California, Maryland, Rhode Island, and Pennsylvania, and is pursuing a license from New York.

"Bringing our laboratory operations in-house is a defining step for Cardio Diagnostics,"

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

Tue, 18 Aug 2026 08:35:00 -0400

The new in-house laboratory facility will give Cardio Diagnostics end-to-end ownership of test processing and expand research capabilities for ongoing and future studies in precision monitoring of cardiovascular health.

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the official launch of its in-house, high complexity CLIA-certified laboratory in Iowa City, Iowa. The new facility gives Cardio Diagnostics end-to-end control over the processing of its multi-omics clinical tests, Epi+Gen CHD™ and PrecisionCHD™, from sample receipt to result delivery, replacing the third-party arrangement

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

Tue, 18 Aug 2026 08:35:00 -0400

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

Tue, 18 Aug 2026 08:35:00 -0400

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

Tue, 18 Aug 2026 08:35:00 -0400

Form 10-Q Cardio Diagnostics Holdi For: Jun 30

Fri, 07 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260807/26891590.html

Form 10-Q Cardio Diagnostics Holdi For: Jun 30

Fri, 07 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260807/26891590.html

Form DEFA14A Cardio Diagnostics Holdi

Fri, 07 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260807/26888291.html

Form DEFA14A Cardio Diagnostics Holdi

Fri, 07 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260807/26888291.html

Form DEF 14A Cardio Diagnostics Holdi For: Sep 18

Wed, 05 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260805/26875063.html

Form DEF 14A Cardio Diagnostics Holdi For: Sep 18

Wed, 05 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260805/26875063.html

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026

Wed, 05 Aug 2026 08:35:00 -0400

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time.

The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, ongoing and planned studies, reimbursement progress, and strategic growth initiatives.

Webcast and Conference

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026

Wed, 05 Aug 2026 08:35:00 -0400

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time.
The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, ongoing and planned studies, reimbursement progress, and strategic growth initiatives.
Webcast and Conference

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026

Wed, 05 Aug 2026 08:35:00 -0400

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time.
The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, ongoing and planned studies, reimbursement progress, and strategic growth initiatives.
Webcast and Conference

Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026

Wed, 05 Aug 2026 08:35:00 -0400

CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) (“Cardio Diagnostics” or the “Company”), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time.
The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, ongoing and planned studies, reimbursement progress, and strategic growth initiatives.
Webcast and Conference

Form ARS Cardio Diagnostics Holdi For: Dec 31

Thu, 23 Jul 2026 16:40:00 -0400
si-local-file:///var/storage/secattach/20260723/26808709.html

Form ARS Cardio Diagnostics Holdi For: Dec 31

Thu, 23 Jul 2026 16:40:00 -0400
si-local-file:///var/storage/secattach/20260723/26808709.html

Form PRE 14A Cardio Diagnostics Holdi For: Sep 18

Mon, 13 Jul 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260713/26762799.html

Form PRE 14A Cardio Diagnostics Holdi For: Sep 18

Mon, 13 Jul 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260713/26762799.html